Pathios Therapeutics Secures $25M in Series B Funding for Cancer Drug Development.

Medincell and AbbVie Partner to Co-Develop Six Long-Acting Injectables.

On April 10, 2024, Vertex Pharmaceuticals ("Vertex") and Alpine Immune Sciences ("Alpine") announced that the parties entered into a definitive agreement. the parties have entered into a definitive agreement.

On April 12, 2024, Arvinas announced that it has entered into an exclusive strategic license agreement with Novartis to collaborate on the development of Arvinas' second-generation androgen receptor (AR) degrader, ARV-766.

On February 28th, US-based Viatris and Swiss firm Idorsia launched a major R&D partnership, with Viatris securing exclusive global rights for two Phase 3 drugs, Selatogrel and Cenerimod, and options for future joint projects.

clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.

On February 21, 2024, Innovent Biologics and ImmVirX unveiled a partnership for clinical research on a combo therapy using sintilimab and the cancer-fighting virus IVX037.

Hutchmed and Inmagene have exercised licensing options for two drug candidates, IMG-007 and IMG-004, as per their strategic collaboration agreement.

On January 24, 2024, Novo Nordisk partnered with EraCal Therapeutics to co-develop an appetite and weight control drug.

On January 30, 2024, Regeneron revealed plans to acquire 2seventy bio's immuno-cell therapy pipeline and related manufacturing capabilities under a new agreement.

Merck Sharp & Dohme (MSD) and Harpoon Therapeutics announced a deal for MSD to purchase Harpoon at $23/share, totaling around $680 million in equity.

Bristol Myers Squibb (BMS) and RayzeBio announced a definitive merger, with BMS acquiring RayzeBio for $62.50/share in a deal valued at about $4.1 billion, netting $3.6 billion after accounting for RayzeBio's $500 million cash.